ROS/RNS as molecular signatures of chronic liver diseases

被引：45

作者：

Che, Zhaodi ^{[1
]}

Zhou, Ziyuan ^{[2
]}

Li, Si-Qi ^{[3
]}

Gao, Lei ^{[4
]}

Xiao, Jia ^{[5
]}

Wong, Nai-Kei ^{[3
]}

机构：

[1] Jinan Univ, Clin Res Inst, Inst Obes & Metab, Affiliated Hosp 1, Guangzhou 510000, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen 518116, Peoples R China

[3] Shantou Univ, Dept Pharmacol, Clin Pharmacol Sect, Med Coll, Shantou 515041, Peoples R China

[4] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510000, Peoples R China

[5] Univ Hlth & Rehabil Sci, Qingdao Hosp, Shandong Prov Key Lab Clin Res Liver Dis, Qingdao 266001, Peoples R China

来源：

TRENDS IN MOLECULAR MEDICINE | 2023年 / 29卷 / 11期

基金：

中国国家自然科学基金;

关键词：

RECEPTOR AGONIST TIRZEPATIDE; CELL-DEATH; NONALCOHOLIC STEATOHEPATITIS; SIGNALING PATHWAY; DUAL GIP; FIBROSIS; FERROPTOSIS; INJURY; ACTIVATION; METABOLISM;

D O I：

10.1016/j.molmed.2023.08.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The liver can succumb to oxidant damage during the development of chronic liver diseases. Despite their physiological relevance to hepatic homeostasis, excessive reactive oxygen/nitrogen species (ROS/RNS) production under pathological con-ditions is detrimental to all liver constituents. Chronic oxidative stress coupled to unresolved inflammation sets in motion the activation of profibrogenic hepatic stellate cells (HSCs) and later pathogenesis of liver fibrosis, cirrhosis, and liver cancer. The liver antioxidant and repair systems, along with autophagic and ferroptotic machineries, are implicated in the onset and trajectory of disease development. In this review, we discuss the ROS/RNS-related mechanisms underlying liver fibrosis of distinct etiologies and highlight preclinical and clinical trials of antifibrotic therapies premised on remediating oxidative/nitrosative stress in hepatocytes or targeting HSC activation.

引用

页码：951 / 967

页数：17

共 119 条

[31] Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials [J].

Harrison, Stephen A. ;

Wong, Vincent Wai-Sun ;

Okanoue, Takeshi ;

Bzowej, Natalie ;

Vuppalanchi, Raj ;

Younes, Ziad ;

Kohli, Anita ;

Sarin, Shiv ;

Caldwell, Stephen H. ;

Alkhouri, Naim ;

Shiffman, Mitchell L. ;

Camargo, Marianne ;

Li, Georgia ;

Kersey, Kathryn ;

Jia, Catherine ;

Zhu, Yanni ;

Djedjos, C. Stephen ;

Subramanian, G. Mani ;

Myers, Robert P. ;

Gunn, Nadege ;

Sheikh, Aasim ;

Anstee, Quentin M. ;

Romero-Gomez, Manuel ;

Trauner, Michael ;

Goodman, Zachary ;

Lawitz, Eric J. ;

Younossi, Zobair .

JOURNAL OF HEPATOLOGY, 2020, 73 (01) :26-39

[32]

Harrison Stephen A, 2020, J Hepatol, V72, P816, DOI 10.1016/j.jhep.2019.11.024

[33] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J].

Harrison, Stephen A. ;

Bashir, Mustafa R. ;

Guy, Cynthia D. ;

Zhou, Rong ;

Moylan, Cynthia A. ;

Frias, Juan P. ;

Alkhouri, Naim ;

Bansal, Meena B. ;

Baum, Seth ;

Neuschwander-Tetri, Brent A. ;

Taub, Rebecca ;

Moussa, Sam E. .

LANCET, 2019, 394 (10213) :2012-2024

[34] Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis [J].

Harrison, Stephen A. ;

Abdelmalek, Manal F. ;

Caldwell, Stephen ;

Shiffman, Mitchell L. ;

Diehl, Anna Mae ;

Ghalib, Reem ;

Lawitz, Eric J. ;

Rockey, Don C. ;

Schall, Raul Aguilar ;

Jia, Catherine ;

McColgan, Bryan J. ;

McHutchison, John G. ;

Subramanian, G. Mani ;

Myers, Robert P. ;

Younossi, Zobair ;

Ratziu, Vlad ;

Muir, Andrew J. ;

Afdhal, Nezam H. ;

Goodman, Zachary ;

Bosch, Jaime ;

Sanyal, Arun J. .

GASTROENTEROLOGY, 2018, 155 (04) :1140-1153

[35] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes [J].

Hartman, Mark L. ;

Sanyal, Arun J. ;

Loomba, Rohit ;

Wilson, Jonathan M. ;

Nikooienejad, Amir ;

Bray, Ross ;

Karanikas, Chrisanthi A. ;

Duffin, Kevin L. ;

Robins, Deborah A. ;

Haupt, Axel .

DIABETES CARE, 2020, 43 (06) :1352-1355

[36] ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis [J].

He, Feng ;

Zhang, Peng ;

Liu, Junlai ;

Wang, Ruolei ;

Kaufman, Randal J. ;

Yaden, Benjamin C. ;

Karin, Michael .

JOURNAL OF HEPATOLOGY, 2023, 79 (02) :362-377

[37] Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection [J].

Hino, Keisuke ;

Nishina, Sohij ;

Sasaki, Kyo ;

Hara, Yuichi .

FREE RADICAL BIOLOGY AND MEDICINE, 2019, 133 :193-199

[38] Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity [J].

Hirao, Hirofumi ;

Nakamura, Kojiro ;

Kupiec-Weglinski, Jerzy W. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (04) :239-256

[39] Fluorescent Probe HKSOX-1 for Imaging and Detection of Endogenous Superoxide in Live Cells and In Vivo [J].

Hu, Jun Jacob ;

Wong, Nai-Kei ;

Ye, Sen ;

Chen, Xingmiao ;

Lu, Ming-Yang ;

Zhao, Angela Qian ;

Guo, Yuhan ;

Ma, Alvin Chun-Hang ;

Leung, Anskar Yu-Hung ;

Shen, Jiangang ;

Yang, Dan .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (21) :6837-6843

[40] Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial [J].

Invernizzi, Pietro ;

Carbone, Marco ;

Jones, David ;

Levy, Cynthia ;

Little, Nicola ;

Wiesel, Philippe ;

Nevens, Frederik ;

study invest .

LIVER INTERNATIONAL, 2023, 43 (07) :1507-1522

← 1 2 3 4 5 6 7 8 9 10 →